| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Erlotinib in previously treated non-small-cell lung cancer.
|
N Engl J Med
|
2005
|
31.48
|
|
2
|
Cancer statistics, 2005.
|
CA Cancer J Clin
|
2005
|
25.65
|
|
3
|
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
|
J Clin Oncol
|
2003
|
11.33
|
|
4
|
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
9.05
|
|
5
|
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
|
Nat Med
|
2002
|
7.06
|
|
6
|
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
|
Blood
|
2003
|
5.07
|
|
7
|
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
|
J Clin Oncol
|
2004
|
4.67
|
|
8
|
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
|
Mol Cancer Ther
|
2003
|
4.09
|
|
9
|
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
|
J Clin Oncol
|
2005
|
3.50
|
|
10
|
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
|
J Clin Oncol
|
2005
|
2.70
|
|
11
|
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
|
Invest New Drugs
|
2005
|
2.30
|
|
12
|
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
|
Cancer
|
2005
|
1.89
|
|
13
|
Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells.
|
Cancer Res
|
1999
|
1.67
|
|
14
|
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
|
Clin Cancer Res
|
2006
|
1.63
|
|
15
|
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
|
J Thorac Oncol
|
2007
|
1.39
|
|
16
|
Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation.
|
J Biol Chem
|
1996
|
1.27
|
|
17
|
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
|
Anticancer Drugs
|
2006
|
1.25
|
|
18
|
The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.
|
Breast Cancer Res
|
2006
|
1.12
|
|
19
|
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
|
J Clin Oncol
|
1997
|
0.95
|
|
20
|
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
|
FASEB J
|
2005
|
0.93
|
|
21
|
Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.
|
Transplant Proc
|
2003
|
0.89
|
|
22
|
Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.
|
Curr Cancer Drug Targets
|
2012
|
0.86
|
|
23
|
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
|
Clin Cancer Res
|
2013
|
0.75
|